Physician profile
Hunter B Moore
NPI 1144519935
$27,894.60
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 95% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $3,179 · 2023: $314 · 2024: $6,503 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,898 · Consulting Fee: $7,838 · Education: $4,558 · Food and Beverage: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,897.67 |
| Consulting Fee | $7,837.50 |
| Education | $4,557.75 |
| Food and Beverage | $1,423.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols Shared Services North America, INC. | $15,908.80 | 2025 | |
| Intuitive Surgical, INC. | $6,495.12 | 2024-2025 | |
| Instrumentation Laboratory Company | $3,084.22 | 2022-2025 | |
| Hemosonics LLC | $1,000.00 | 2021 | |
| Haemonetics Corporation | $573.00 | 2022-2025 | Teg6s Hemostasis System, Teg Manager |
| Tela Bio, INC. | $338.91 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Boston Scientific Corporation | $128.01 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Ethicon US, LLC | $75.61 | 2023-2025 | Surgicel Nu-Knit, Enseal, Evarrest |
| Amag Pharmaceuticals, INC. | $35.30 | 2022 | |
| Novo Nordisk INC | $34.60 | 2025 | Ozempic |
| Octapharma USA, INC. | $31.39 | 2025 | Fibryga |
| Madrigal Pharmaceuticals | $29.17 | 2024 | Resmetirom |
| Pacira Pharmaceuticals Incorporated | $27.94 | 2024 | Exparel |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2025 | Bylvay |
| Innovation Technologies INC | $25.84 | 2024 | Irrisept |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.98 | 2025 | Signia |
| Mimedx Group, INC. | $19.74 | 2024 | |
| Orphalan INC | $19.36 | 2024 | Cuvrior |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.